Notifying patients and providers about the rosiglitazone cardiovascular safety alert led to sweeping changes in drug therapy that were initiated by both physicians and patients.
Kathleen B. Orrico, PharmD, BCPS
Advertisement
Articles by Kathleen B. Orrico, PharmD, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
2
Counseling Vitiligo Patients on Time to Repigmentation
3
5 August FDA Approvals Marked by Novelty, Pushback
4
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
5